openpr.com
Cure8 news brief
Why This Matters
Market and late-stage trial updates can indicate which new therapies may become available and influence treatment options, access, and research priorities for Crohn's disease over the coming years.
Who Should Pay Attention
Adult patients with Crohn's disease, clinicians treating IBD, researchers in IBD drug development, and stakeholders interested in biologics and emerging therapies.
Study Snapshot
Story typePress release
Evidence typeMarket or Business News
Source depthFull source text
What To Know
This article is a press summary of a market research report (DelveInsight) covering Crohn's disease market forecasts, recent clinical trial results, regulatory filings, and company development updates.
It highlights AbbVie's risankizumab (SKYRIZI) Phase 3 AFFIRM results and EMA filing for subcutaneous induction, Sandoz's natalizumab biosimilar (Tyruko) availability, gomab/ontunisertib Phase IIb progression for fibrostenosing Crohn's disease, and other industry milestones.
The piece is written from a market/industry perspective and links to the paid DelveInsight report for more detail. It summarizes trial outcomes and regulatory events reported by companies and public releases but does not provide full study data or methods in this article. For clinical decisions, consult primary trial reports or clinical guidelines.
adults with Crohn's disease (especially those interested in new biologic and small-molecule options), clinicians following emerging treatments and regulatory updates, researchers tracking drug development, and investors or policymakers monitoring market trends.
this is a secondary market-report summary and includes company-reported results and regulatory filings; such summaries can omit detailed safety, methodology, or peer-reviewed publication context. The underlying DelveInsight report appears to be a paid market analysis.
Keep In Mind
The article summarizes a commercial market report and company press releases. trial results and regulatory filings mentioned should be checked against primary sources (peer-reviewed publications, clinical trial registries, and regulatory agency announcements) for full details.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationopenpr.com
AuthorsDelveInsight Business Research
Indexed viaGoogle News
Source typeWeb article
PublishedSep 1, 2026, 8:12 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
How Biologics Are Changing the Global Burden of Inflammatory Bowel Disease: A Review.
Biologics and newer small molecules have markedly changed IBD care and outcomes for many patients, but their population-level impact depends on access, cost, and how they are used. Understanding this helps patients and...
To Your Good Health: Aggressive treatment for Crohn's - Tribune Chronicle -
Guidelines recommend treating objective inflammation even when symptoms are mild because untreated disease can cause complications; the article describes escalation to risankizumab due to endoscopic inflammation, high...
Highlights of the 2026 European Crohn's and Colitis Conference: redefining the IBD care continuum.
ECCO 2026 presented multiple studies that could change IBD care across prevention, medical therapy (including pediatric data), complication‑directed strategies (perianal fistula), and technology‑assisted monitoring....